Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biodesix Inc (BDSX)

Biodesix Inc (BDSX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,406
  • Shares Outstanding, K 42,094
  • Annual Sales, $ 54,510 K
  • Annual Income, $ -43,160 K
  • 60-Month Beta 1.74
  • Price/Sales 1.10
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BDSX with:

Options Overview Details

View History
  • Implied Volatility 141.19% ( -198.67%)
  • Historical Volatility 167.67%
  • IV Percentile 57%
  • IV Rank 21.23%
  • IV High 583.23% on 09/23/22
  • IV Low 22.04% on 08/10/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 392
  • Open Int (30-Day) 266

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.34
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +46.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +34.00%
on 11/10/22
2.0000 -33.00%
on 11/30/22
+0.2700 (+25.23%)
since 11/07/22
3-Month
0.9550 +40.31%
on 10/27/22
2.2100 -39.37%
on 09/09/22
-0.2600 (-16.25%)
since 09/07/22
52-Week
0.9550 +40.31%
on 10/27/22
5.9973 -77.66%
on 01/05/22
-4.3300 (-76.37%)
since 12/07/21

Most Recent Stories

More News
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of...

BDSX : 1.3400 (unch)
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its...

BDSX : 1.3400 (unch)
Biodesix Announces Proposed Public Offering of Common Stock

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of...

BDSX : 1.3400 (unch)
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has obtained a term loan facility for up to $50 million from Perceptive...

BDSX : 1.3400 (unch)
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Wallace Akerley, MD, medical oncologist at the University of Utah Huntsman...

BDSX : 1.3400 (unch)
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BDSX : 1.3400 (unch)
VTRS : 10.90 (-0.27%)
Biodesix Announces Third Quarter 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for third quarter ended September 30,...

BDSX : 1.3400 (unch)
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September...

BDSX : 1.3400 (unch)
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the award of a U.S. Federal Supply Schedule contract which includes the...

BDSX : 1.3400 (unch)
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three data presentations will occur at the CHEST 2022 Annual Meeting...

BDSX : 1.3400 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes...

See More

Key Turning Points

3rd Resistance Point 1.4200
2nd Resistance Point 1.3800
1st Resistance Point 1.3600
Last Price 1.3400
1st Support Level 1.3000
2nd Support Level 1.2600
3rd Support Level 1.2400

See More

52-Week High 5.9973
Fibonacci 61.8% 4.0711
Fibonacci 50% 3.4762
Fibonacci 38.2% 2.8812
Last Price 1.3400
52-Week Low 0.9550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar